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Edited by Berend WieringaAbstract Peroxisome proliferator-activated receptor-delta
(PPARd) activation enhances skeletal muscle fatty acid oxida-
tion and improves whole body glucose homeostasis and insulin
sensitivity. Recently, GW501516, a selective PPARd agonist,
was reported to increase glucose uptake in human skeletal myo-
tubes by an AMPK-dependent mechanism that may contribute to
the improved glucose tolerance. Here, we demonstrate that
whilst GW501516 increases expression of PGC-1a and CPT-1
and stimulates fatty-acid oxidation in L6 myotubes, it fails to en-
hance insulin sensitivity, AMPK activity or glucose uptake and
storage. Our ﬁndings exclude sarcolemmal glucose transport as
a potential target for the therapeutic action of PPARd agonists
in skeletal muscle.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Metabolism1. Introduction
Peroxisome proliferator-activated receptor-delta (PPARd) is
abundant in many tissues, including liver and muscle [1], and is
activated by endogenous ligands such as polyunsaturated fatty
acids and eicosanoids. The recent development of speciﬁc
PPARd agonists [2] and the generation of transgenic mice that
either lack or over express an activated form of PPARd in skel-
etal muscle has revealed that receptor activation confers resis-
tance to obesity and improves metabolic proﬁles as a result of
enhanced fatty acid oxidation, mitochondrial biogenesis and
muscle ﬁber-type switching [3]. However, the underlying mech-
anism promoting glucose-lowering and insulin-sensitivity in re-
sponse to activation of PPARd remains poorly understood.
Kraemer et al. have reported that treatment of primary human
skeletal muscle cells or murine C2C12 myotubes with the
PPARd agonist GW501516 directly stimulates basal and insu-
lin-stimulated glucose uptake [4] and work by the same group
has recently suggested that this enhancement in hexose uptakeAbbreviations: PPAR, peroxisome proliferator-activated receptor;
PGC-1a, peroxisome proliferator-activated receptor-gamma coactiva-
tor 1a; CPT-1, carnitine palmitoyl-transferase-1; GW, GW501516
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doi:10.1016/j.febslet.2007.08.072is mediated via an AMPK-dependent mechanism [5]. In con-
trast, work from Terada et al. [6] has shown that exposure
of isolated rat skeletal muscles to GW501516 had no detect-
able eﬀect on glucose uptake. Given the importance of skeletal
muscle as a target of insulin action and as a major site of whole
body glucose disposal we have investigated the eﬀects of
GW501516 on glucose utilisation in rat L6 skeletal muscle
myotubes, which retain many of the archetypal features and
responses of mammalian skeletal muscle such as insulin-stimu-
lated glucose transport and glycogen synthesis. We show here
that whilst GW501516 promotes lipid oxidation and enhances
the expression of carnitine palmitoyltransferase-1 (CPT-1) and
peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1-a, an important regulator of mitochondrial
biogenesis), it had no signiﬁcant eﬀect upon glucose uptake
and oxidation, glycogen synthesis, AMPK activity and, more-
over, did not sensitise myotubes to insulin or protect them
from palmitate-induced insulin resistance.2. Materials and methods
2.1. Materials
a-Minimal essential medium (a-MEM), foetal bovine serum (FBS),
and antibiotic/antimycotic solution were from Life Technologies (Pais-
ley, Scotland, UK). All other reagent-grade chemicals including insulin,
bovine serum albumin (BSA), palmitate, anti-actin antibody were ob-
tained from Sigma–Aldrich (Poole, UK). Antibodies against PKB,
phospho-PKB-Ser473, phospho-GSK3b-Ser9, phospho-p44-42MAPK
Thr202/Tyr204, phospho-p70S6K-Thr389 and phospho-(Thr172) AMPK
were from New England Biolabs (Hitchin, Herts, UK). Anti-CPT-1
antibody was obtained from Alpha Diagnostic International (San
Antonio, USA). Anti-PPARd antibody and GW501516 were a gener-
ous gift fromDr. Colin Palmer (Ninewells Hospital, University of Dun-
dee, UK). Anti-PGC-1a antibody was kindly provided by Dr. K. Baar
(University of Dundee, UK). U-[14C] D-glucose and uridine diphospho-
[6-3H] D-glucose were purchased from Amersham Biosciences, while 2-
deoxy-[3H] D-glucose from Perkin Elmer Life Sciences (Cambridge,
UK).2.2. Cell culture
L6 cells were cultured to myotubes in a-MEM as previously de-
scribed [7]. Myotubes were pretreated with GW501516 for 24 h. After
8 h culture media was replaced with fresh medium containing 2% FBS
(v/v), 1% (v/v) antibiotic/antimycotic and 2% BSA (w/v) and
GW501516 for further 16 h, but supplemented with palmitate (conju-
gated to BSA) or with the vehicle solution. Cells were ﬁnally serum de-
prived during the last 2 h prior to any treatment with insulin (100 nM).
Insulin was added to the cell bathing solution during the penultimate
30 min incubation period for glucose uptake assays or for the ﬁnal
10 min for cells that were being lysed for immunoblotting studies.blished by Elsevier B.V. All rights reserved.
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L6 myotubes were incubated for times and with the appropriate con-
centration of eﬀectors as indicated in the ﬁgure legends. Following
treatment, cells were washed three times by rapid aspiration with
0.9% (w/v) ice-cold saline and then lysed using lysis buﬀer [50 mM Tris,
pH 7.4, 0.27 M sucrose, 1 mM Na-orthovanadate, pH 10, 1 mM
EDTA, 1 mM EGTA, 10 mM Na-b-glycerophosphate, 50 mM NaF,
5 mMNa pyrophosphate, 1% (w/v) Triton X-100, 0.1% (v/v) 2-mercap-
toethanol, 0.1 lMmicrocystin-LR and protease inhibitors]. Whole cell
lysates were centrifuged (15000 · g, 4 C for 10 min) and stored at
20 C. The protein content of membrane samples was determined
using the Bradford assay [8]. Cell lysates (50 lg protein) were subjected
to SDS–PAGE on 10% resolving gels and transferred onto Immobilon-
P or Hybond-C membranes (Millipore, Harts, UK), as described previ-
ously [7]. Membranes were probed with primary antibodies against pro-
teins of interest. Primary antibody detection was performed using either
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG or anti-
mouse IgG and visualized using enhanced chemiluminescence (Pierce-
Perbio Biotechnology, Tattenhall, Cheshire, UK) on Kodak X-OMAT
ﬁlm (Eastman-Kodak, Rochester, Kent, UK).
2.4. Glucose uptake
Following appropriate treatment, L6 myotubes were washed three
times with HEPES-Buﬀered Saline (HBS; 140 mM NaCl, 20 mM
HEPES, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2, pH 7.4). Glucose
uptake was assayed by incubation with 10 lM 2-deoxy-[3H] D-glucose
(1 lCi/ml) for 10 min [7]. Nonspeciﬁc binding was determined by
quantifying cell-associated radioactivity in the presence of 10 lM cyto-
chalasin B. Radioactive medium was aspirated prior to rapidly wash-
ing adherent cells three times with 0.9% (w/v) ice-cold saline. Cells
were subsequently lysed in 50 mM NaOH and radioactivity quantiﬁed
using a Beckman LS 6000IC scintillation counter. Protein concentra-
tion in cell lysates was determined using the Bradford reagent as de-
scribed previously [8].
2.5. Glycogen synthesis and glucose oxidation assay
Following treatment muscle cells were incubated with HBS contain-
ing 5 mM glucose and 2 lCi/ml [U-14C-D-glucose] for 1 h at 37 C.
Following this incubation period, the culture medium was carefully re-
moved and set aside in a culture ﬂask for analysis of liberated [14C]
CO2, whilst the cells were used for determination of label into cellular
glycogen as described before [9]. Brieﬂy, a glass ﬁbre ﬁlter (Whatman)
was dipped in 1 M KOH and suspended over the medium in the cul-
ture ﬂask. The medium was then acidiﬁed by injection of 60% (v/v) per-
chloric acid and the ﬂasks were placed at 37 C with mild agitation for
2 h. The amount of labeled CO2 released from the medium and cap-
tured on the ﬁlters was then measured by liquid scintillation counting.
For analysis of glycogen synthesis, cells were lysed in 10 M KOH and
boiled for 30 min. To assist precipitation, 5 mg/ml glycogen was added
together with 66% (v/v) ethanol and lysates held overnight at 4 C. Fol-
lowing this period samples were centrifuged, the supernatant was re-
moved by aspiration and ethanol (66%, v/v) was added again.
Samples were kept at 20 C for 4 h prior to being centrifuged at
13000 · g for 20 min. The glycogen-containing pellet was dissolved
in water and radioactivity associated with the pellet measured by scin-
tillation counting.
2.6. Fatty acid oxidation
L6 myotubes were incubated with GW501516 or phenformin for
times and at concentrations indicated in ﬁgure legends, but serum
starved for 2 h prior to assaying fatty acid oxidation. Muscle cells were
washed with HBS and subsequently incubated with media containing
0.75 mM palmitate (conjugated to BSA)/[14C] palmitate (2 lCi/ml)
for 2 h. Following this incubation period, 1 ml of the culture medium
was carefully transferred to a sealable tube, the cap of which housed a
Whatman (GF/B) ﬁlter paper disc that had been pre-soaked with 1 M
KOH. 14CO2 trapped in the media was then released by acidiﬁcation of
media using 60% (v/v) perchloric acid and gently agitating the tubes at
37 C for 2 h. Radioactivity that had become adsorbed onto the ﬁlter
discs was subsequently quantitated by liquid scintillation counting.
2.7. Glycogen synthase assay
Brieﬂy, assay buﬀer (67 mM Tris, pH 7.5, 5 mM dithiothreitol,
89 mM UDP-glucose, 6.7 mM EDTA, 13 mg/ml glycogen, 1 lCi perassay uridine diphospho-[6-3H] D-glucose) was added to 45 ll cell ly-
sate in the presence and absence of 20 mM glucose-6-phosphate. After
a 30-min incubation at 37 C the reaction was terminated by spotting
the reaction mixture onto 31ETCHR Whatman ﬁlter paper (What-
man, Maidstone, UK) and washed three times in 66% (v/v) ethanol
for 20 min. Filters were ﬁnally washed in acetone and air dried before
incorporation of glucose from uridine diphospho-[6-3H] D-glucose into
glycogen was quantiﬁed using a Beckman LS6000IC scintillation coun-
ter. GS activity was expressed as a ratio of the activity in the absence of
glucose-6-phosphate over that in the presence of the allosteric activator
[10].
2.8. Statistical analyses
Data analysis were performed using GraphPad Prism software and
considered statistically signiﬁcant at values of P < 0.05. Bands from
immunoblots were quantiﬁed using ImageJ software.3. Results
3.1. Eﬀects of GW501516 upon PGC-1a and CPT-1 expression
and fatty acid oxidation
Activation of PPARd is known to aﬀect the expression of
genes involved in lipid catabolism, such as peroxisome prolif-
erator-activated receptor-gamma coactivator 1a (PGC-1a)
and carnitine palmitoyl-transferase-1 (CPT-1) [11]. In an at-
tempt to establish whether activation of PPARd modiﬁes fuel
use in skeletal muscle we assessed the eﬀects of incubating L6
myotubes with GW501516, a potent and selective PPARd ago-
nist [12,13] upon PGC-1a and CPT1 abundance. Fig. 1A
shows that PPARd is endogenously expressed in L6 myotubes
and that, consistent with previous ﬁndings [11,14], treatment
with the GW501516 for 24 h enhanced the abundance of both
PGC-1a and CPT-1 by 2.8- and 1.7-fold, respectively. Treat-
ment with higher concentrations of the compound or longer
exposure of cells to the drug did not result in greater changes
in expression of these two marker proteins (data not shown).
In line with the increased expression of both PGC-1a and
CPT-1, L6 myotubes exhibit a 2.2-fold increase in fatty acid
(palmitate) oxidation following treatment with the PPARd
agonist for 24 h (Fig. 1B). In this latter experiment, L6 myotu-
bes were also incubated with phenformin (as a positive con-
trol). This biguanide stimulates fatty acid oxidation via its
stimulatory eﬀect upon AMPK which induces an attendant
reduction in malonyl-CoA that then allows an increase in
mitochondrial fatty acid uptake and oxidation.
3.2. GW501516 does not improve insulin sensitivity nor does it
antagonise palmitate-induced insulin resistance in L6
myotubes
Having established that GW501516 stimulates PPARd-di-
rected changes in the expression of PGC-1a and CPT-1 and
promotes fatty acid oxidation in L6 myotubes, we subse-
quently investigated whether activation of PPARd modiﬁes
insulin action in these cells. Fig. 2 shows that treatment of
muscle cells with the agonist alone had no signiﬁcant eﬀect
on the phosphorylation status of MAPK, PKB, GSK3b or
that of p70S6K, which are known to be activated in response
to insulin and growth factors (compare lanes 1 and 5). Subject-
ing muscle cells to an acute insulin challenge induced phos-
phorylation/activation of all four protein kinases (compare
lanes 1 and 2), the extent of which, based on analyses of three
separate experiments, was not altered in myotubes that had
been preincubated with GW501516 for 24 h (Fig. 2, compare
Fig. 1. Eﬀect of GW501516 on the expression of PGC-1 a, CPT-1, PPARd and on fatty acid oxidation in L6 myotubes. (A) L6 myotubes were
treated with or without 1 lM GW501516 (GW) for 24 h. Controls were treated with vehicle solution alone. Whole cell lysates were prepared and
immunoblotted with antibodies against PGC-1a, CPT-1, actin and PPARb/d. Immunoblots from three separate experiments were quantiﬁed and
presented in the corresponding bar graphs. (B) Palmitate oxidation was assessed in L6 myotubes as described in Section 2 following prior incubation
of cells with 1 lM GW501516 for 24 h or 0.2 mM Phenformin for 2 h. Values are expressed as a fold change relative to control and are
means ± S.E.M. *P < 0.05, compared with the control.
Fig. 2. Eﬀect of GW501516 on the phosphorylation/activation status
of PKB, GSK3b, p70S6K, MAPK in L6 myotubes. L6 myotubes were
pre-incubated with 1 lM GW501516 for 24 h prior to further
incubation with the agonist in the absence or presence of 0.75 mM
palmitate for 16 h. Muscle cells were serum-starved for last 2 h of this
treatment period and cells exposed to 100 nM insulin or saline (vehicle)
during the penultimate 10 min. Whole cell lysates were prepared and
immunoblotted with phospho-speciﬁc antibodies against PKB-Ser473,
GSK3b-Ser9, p70S6K-Thr389, p44-42MAPK Thr202/Tyr204, total PKB
and actin. Representative immunoblots from three separate experi-
ments are presented.
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exposure of L6 myotubes to 0.75 mM palmitate (16:0) for
16 h induces a maximal suppression in the insulin-dependent
regulation of signaling intermediates such as PKB and GSK3
and that of distal responses such as glucose transport [9]. Gi-
ven that insulin resistance associated with prolonged palmitate
treatment is associated with increased de novo synthesis of cer-
amide from palmitate [9], we hypothesized that GW501516
may protect against palmitate-induced insulin resistance by
chanelling the fatty acid towards oxidation rather than cera-
mide synthesis [15]. However, whilst GW501516 elevates palm-
itate oxidation (Fig. 1B) the PPARd agonist was unable to
antagonise the impaired activation of the four diﬀerent kinases
in response to long term palmitate incubation (Fig. 2, compare
lanes 4 and 8). Similar ﬁndings were also obtained when using
sub-maximal concentrations of palmitate that were still capa-ble of reducing activation of these signaling proteins (data
not shown).
3.3. Eﬀects of GW501516 on glucose uptake, glucose oxidation
and glycogen synthesis
Kramer et al. have suggested that GW501516 potentiates
insulin stimulated glucose uptake in cultured adipocytes and
that the compound enhances basal and insulin-stimulated glu-
cose uptake in human skeletal muscle [4]. More recently, Kra-
mer et al. have proposed that the ability of GW501516 to
stimulate glucose uptake in human skeletal muscle is mediated
via activation of the AMPK rather than PPARd itself [5]. In
the absence of any detectable change in insulin signalling we
assessed whether activation of PPARd may directly inﬂuence
glucose uptake in L6 myotubes or promote activation of
AMPK. Insulin (100 nM) acutely stimulates glucose uptake
by 75% (Fig. 3A), but, in line with previous work [16], this
stimulation was severely blunted by prior incubation of muscle
cells with palmitate for 16 h (Fig. 3). Analysis of glucose up-
take in muscle cells that had been subjected to incubation with
GW501516 revealed that the agonist had no detectable eﬀect
on basal or insulin-stimulated glucose uptake and nor was it
able to ameliorate the insulin-desensitising eﬀects of palmitate.
To exclude the possibility that any eﬀects of GW501516 on
insulin-stimulated glucose uptake may have been masked by
using a maximally eﬀective concentration of insulin the eﬀects
of the compound on glucose uptake in the presence of a
sub-maximal insulin concentration (10 nM) were also investi-
gated. However, at this dose insulin induces only a modest
increase in glucose uptake (20%), which was not enhanced
in any signiﬁcant manner in muscle cells that had been pre-
treated with GW501516 (100 nM) for 24 h (data not shown).
Kramer et al. have recently reported that GW501516 invokes
changes in the AMP:ATP ratio in human skeletal myotu-
bes that promotes an increase in AMPK activity and induces
a consequential increase in glucose uptake [5]. Fig. 3B shows
that whilst phosphorylation of AMPK on its T-loop residue
(T172) was enhanced signiﬁcantly in L6 myotubes following
acute exposure to phenformin (a well established activator
of AMPK), treatment of muscle cells with GW501516 for
the periods indicated did not signiﬁcantly alter AMPK phos-
phorylation over and above that observed in unstimulated
cells.
Fig. 3. Eﬀect of GW501516 on basal, insulin-stimulated and insulin-resistant glucose uptake and AMPK phosphorylation in L6 myotubes. (A)
Uptake of 2-deoxyglucose was assayed in L6 myotubes following preincubation with 1 lM GW501516 for 24 h prior to further incubation with the
agonist in the absence or presence of 0.75 mM palmitate for 16 h. Muscle cells were serum-starved during the last 2 h of the treatment period and
exposed to 100 nM insulin or saline (vehicle) during the penultimate 30 min. Values are means ± S.E.M. of ﬁve separate experiments each performed
in triplicate. *P < 0.05, compared with the respective control. (B) L6 myotubes were treated in the absence or presence of 0.2 mM phenformin for 1 h
or 1 lM GW501516 for times indicated. Myotubes were lysed and subjected to SDS-PAGE and immunoblotting with antibodies against phospho
(T172)-AMPK or actin (as a loading control). The blots are representative of data from at least three separate experiments.
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glucose oxidation and glycogen synthesis. In line with evidence
from the literature, insulin induced a modest increase (30%)
in glucose oxidation, but a more robust enhancement (3-
fold) in glycogen synthesis (Figs. 4A and B). Treatment with
GW501516 had no detectable eﬀect on basal rates of glucose
oxidation or glycogen synthesis and did not improve sensitiv-
ity of either process when cells were cotreated with the drug
and insulin. Preincubation of L6 myotubes with palmitateFig. 4. Eﬀect of GW501516 on glucose oxidation, glycogen synthesis and
incubated in the absence or presence of 1 lM GW501516 for 24 h prior to
0.75 mM palmitate for 16 h. At the end of this period medium was replace
absence or presence of insulin and assayed for glucose oxidation (A) or ly
assaying glycogen synthase as described in Section 2. Values are means ±
*P < 0.05, compared with the respective control (vehicle only).blunted the insulin-induced increase in glucose oxidation and
glycogen synthesis and this inhibition was not anatgonised
by cell exposure to GW501516 (Figs. 4A and B). Consistent
with the glycogen synthesis data, analysis of glycogen synthase
activity revealed that GW501516 pre-treatment had no stimu-
latory eﬀect on this enzyme per se, did not potentiate its acti-
vation by insulin and, moreover, was unable to ameliorate the
insulin-desensitising eﬀects of plamitate on synthase activity
(Fig. 4C).glycogen synthase activity in L6 myotubes. L6 myotubes were pre-
further incubation with agonist/vehicle in the absence or presence of
d with HBS buﬀer containing 5 mM glucose (2 lCi/ml [U-14C]) in the
sed for determination of glycogen synthesis (B), or (C) processed for
S.E.M. of three separate experiments each performed in triplicate.
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Skeletal muscle expresses all three (a, c and d) subtypes of
peroxisome proliferator activated receptors and their activa-
tion regulates transcriptional programmes that aﬀect a number
of important biological processes. Activation of PPARa, for
example, has been shown to promote fatty acid oxidation
and elicit a thermogenic response in skeletal muscle as a con-
sequence of inducing expression of genes for fatty acid trans-
port and uncoupling proteins [17,18]. In contrast, activation
of PPARc has a strong inﬂuence upon systemic lipid and glu-
cose homeostasis that arises via orchestrated changes in the
expression of numerous genes encoding, for example, adipo-
cyte factors (e.g. adiponectin, resistin, IL-6 and TNFa), nutri-
ent transporters or lipogenic enzymes in a manner that acts to
positively enhance insulin action and fuel storage not only
within adipocytes, but also in other tissues such as skeletal
muscle where the receptor is expressed in lower abundance
[19]. Although PPARd is more ubiquitously expressed it has
been the focus of considerable recent interest with regards its
potential as a drug target for combating the metabolic syn-
drome [20]. This interest stems from the ﬁnding that targeted
over expression of a constitutively active form of PPARd in
adipose tissue or skeletal muscle protects rodents against
diet-induced obesity and elevates fatty acid oxidation as a re-
sult of inducing expression of genes involved in energy dissipa-
tion [3,21]. Similarly, in vitro based studies in cultured muscle
cells that utilise the PPARd agonist, GW501516, have shown
that receptor activation promotes expression of genes impor-
tant for fatty acid uptake, lipid catabolism and energy expen-
diture [11,14]. An important consequence of an increase in
skeletal muscle fatty acid oxidation associated with sustained
activation of PPARd (as is the case in mice over-expressing
the active form of the receptor in skeletal muscle) is a signiﬁ-
cant lowering of intramuscular triglyceride [3]. Since skeletal
muscle insulin sensitivity is negatively correlated with an in-
crease in muscle triglyceride [22], reduction in the latter might,
therefore, be expected to improve insulin action and glucose
disposal in skeletal muscle. Intriguingly, whilst recent work
has shown that GW501516 stimulates glucose uptake in pri-
mary human skeletal myotubes this stimulatory eﬀect appears
to be independent of any improvement in insulin sensitivity or
indeed activation of PPARd [5,23]. The apparent stimulation
in hexose uptake has been attributed to a change in intramus-
cular energy status that results in activation of AMPK, which
is then proposed to signal an increase in glucose uptake [5].
The reported increase in glucose uptake seen in response to
an acute (1 h) challenge of human myotubes with GW501516
appears unaltered, in terms of magnitude, when myotubes
were exposed to the drug for a period of 18 h. Despite the in-
creased uptake of glucose these authors did not observe any
associated increase in muscle glycogen content suggesting that
glucose is primarily channeled for oxidation in response to
GW501516 in human skeletal myotubes [5]. However, the
stimulation of glucose uptake triggered by GW501516 is not
an unequivocal ﬁnding and reports exist in the literature show-
ing that this compound either fails to exert any eﬀect on
glucose uptake [6] or acts to suppress glucose utilisation as a
result of a switch in substrate preference from carbohydrates
to lipids in isolated rat skeletal muscles [24]. In the current
study, we too have been unable to observe any direct eﬀect
of GW501516 on glucose utilisation (transport and oxidation),glycogen synthesis or upon insulin signaling in L6 myotu-
bes. Furthermore, incubation of muscle cells with 1 lM
GW501516, a concentration that enhances fatty acid oxidation
and increases the expression of CPT1 and PGC1a in our exper-
imental system, failed to elicit any substantive increase in
AMPK phosphorylation irrespective of whether muscle cells
had been exposed to the compound acutely (1–2 h) or for more
prolonged periods of 24 h. This latter ﬁnding is in line with the
work of Terada et al. [6] who also were unable to detect
changes in muscle AMPK activity and is fully consistent with
the lack of any detectable GW501516-mediated increase in glu-
cose uptake in L6 myotubes (this study) and isolated rat epit-
rochlearis and soleus muscles [6].
Although the reasons that underlie the apparent discrepancy
between our ﬁndings and those reported by Kramer et al. re-
main unclear, our observations are broadly consistent with
those of Terada et al. [6] and Brunmair et al. [24] and suggest
that it is highly unlikely that modulation of glucose uptake in
skeletal muscle per se serves as a target for the therapeutic ac-
tion of PPARd agonists. If this proposition is correct then how
is the impaired insulin sensitivity and glucose tolerance in mice
lacking PPARd explained? Using genetic and pharmacologic
approaches, Lee et al. [25] have very elegantly shown that, in
addition to stimulating skeletal muscle fatty acid oxidation,
PPARd also inhibits release of free fatty acids from adipocytes
and contributes to the homeostatic control of blood glucose by
suppressing hepatic glucose output. The latter involves pro-
moting an increase in glucose ﬂux through the pentose-phos-
phate pathway and enhancing hepatic fatty acid synthesis
[25]. Consequently, the improved glucose tolerance and insulin
sensitivity that is observed at the level of the whole organism is
likely to reﬂect a combinatorial eﬀect of PPARd actions in li-
ver, skeletal muscle and adipose tissue that collectively induce
a beneﬁcial shift in metabolism and insulin action.
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